Medical uses
Bicalutamide is approved for and mainly used in the following indications:
Metastatic prostate cancer (mPC) in men in combination with a gonadotropin-releasing hormone (GnRH) analogue or surgical castration at 50 mg/day
Locally advanced prostate cancer (LAPC) in men as a monotherapy at 150 mg/day (not approved for this use in the United States)In Japan, bicalutamide is uniquely used at a dosage of 80 mg/day both in combination with castration and as a monotherapy in the treatment of prostate cancer.Bicalutamide is also employed for the following off-label (non-approved) indications:

To reduce the effects of the testosterone flare at the initiation of GnRH agonist therapy in men
Androgen-dependent skin and hair conditions such as acne, seborrhea, excessive hair growth, and scalp hair loss in women as well as high testosterone levels due to polycystic ovary syndrome (PCOS) in women, at 25 to 50 mg/day generally in combination with a birth control pill
Feminizing hormone therapy for transgender women in combination with an estrogen usually at 50 mg/day
Peripheral precocious puberty in boys at 12.5 to 100 mg/day in combination with an aromatase inhibitor like anastrozole, especially for familial male-limited precocious puberty (testotoxicosis)
Overly long-lasting erections in men at 50 mg per week to 50 mg every other dayThe medication has been suggested for but has uncertain effectiveness in the following indication:

Hypersexuality and paraphilias, particularly in combination with chemical castrationFor more information on these uses, see the medical uses of bicalutamide article. Available forms
Bicalutamide is available for the treatment of prostate cancer in most developed countries, including over 80 countries worldwide.
Different dosing schedules have been proposed such as 500 mg/day for one week or 250 mg/day for two weeks each followed by a drug-free period of three or two weeks, totaling 3 months of treatment including the drug-free periods. Such intermittent dosing schedules appear to be as effective as continuous regimes. Chemistry
Terbinafine hydrochloride is a white crystalline powder that is freely soluble in methanol and dichloromethane, soluble in ethanol, and slightly soluble in water.Terbinafine is produced from olefin metathesis of 1,3-dichloropropene and neohexene followed by reaction with N-methyl-1-naphthalenemethanamine.Despite its name it does not contain terbium. History
Terbinafine first became available in Europe in 1991 and in the United States in 1996. The U.S. Food and Drug Administration has approved the first generic versions of prescription Lamisil (terbinafine hydrochloride) tablets. The remaining patent or exclusivity for Lamisil expired on June 30, 2007. On September 28, 2007, the FDA stated that terbinafine is a new treatment approved for use by children age four and up. The antifungal granules can be sprinkled on a childs food to treat ringworm of the scalp, tinea capitis.In the United States the price in 1999 was $547 for a 12-week course; this fell to $10 by 2015, after the patent had expired. Society and culture
Brand names
Terbinafine is sold in India as Terboderm by Omega Pharma and Tyza (Abbott Healthcare).